摘要
目的:探讨比索洛尔联合托拉塞米治疗慢性心力衰竭的临床疗效及安全性。方法:选择2015年1月至2018年1月期间惠州市博罗县人民医院老年病风湿免疫科收治的110例慢性心力衰竭患者,男67例,女43例,年龄51~70岁。采用随机数字表法将患者分为比索洛尔组和联合托拉塞米组,每组55例。在常规抗心力衰竭治疗的基础上,比索洛尔组和联合托拉塞米组分别口服比索洛尔及比索洛尔联合托拉塞米。记录两组治疗前、后NYHA分级情况,患者治疗14 d后疗效与不良反应发生情况,同时记录患者治疗前、后血压情况与电生理指标。结果:治疗前,两组NYHA分级比较差异无统计学意义(P>0.05),治疗后,联合托拉塞米组Ⅰ级与Ⅱ级例数多于比索洛尔组(22例比13例,20例比12例),Ⅲ级与Ⅳ级例数少于比索洛尔组,差异具有统计学意义(P<0.05)。治疗后,联合托拉塞米组总有效率为96.4%(53/55例),比索洛尔组为74.5%(41/55例),差异具有统计学意义(P<0.05)。联合托拉塞米组收缩压与舒张压均低于比索洛尔组[(106±10)比(111±11),(76±10)比(80±10),P<0.05]。两组不良反应与不良事件发生率比较,差异无统计学意义(P>0.05)。两组电生理指标均下降,联合托拉塞米组下降更明显(P<0.05)。结论:比索洛尔联合托拉塞米治疗慢性心力衰竭患者安全、有效。
Objective:To explore the clinical efficacy and safety of bisoprolol combined with torasemide in the treatment of chronic heart failure.Methods:One hundred and ten patients with chronic heart failure in Boluo County People’s Hospital from January 2015 to January 2018,both of sexes,51-70 years old,were divided into bisoprol group and combined with torasemil group by random number table method,with 55 cases in each group.On the basis of conventional anti-heart failure treatment,the patients were given oral administration of bisoprolol in bisoprolol group,bisoprolol combined with torasemide in combined with torasemide group.NYHA classification and electrophysiological indicators were recorded before and after the treatment in the two groups.Efficacy and adverse reactions were recorded after 14 days of treatment.Results:Before the treatment,there was no significant difference in NYHA classification between the two groups(P>0.05).After the treatment,the number of gradeⅠandⅡcases was more in combined with tolasemide group than that in bisoprolol group(22 cases vs.13 cases,20 cases vs.12 cases),and the number of gradeⅢandⅣcases was less than that in bisoprolol group(P<0.05).The total effective rate was 96.4%(53/55 cases)in combined with torasemil group and 74.5%(41/55 cases)in bisoprolol group(P<0.05).Both systolic and diastolic blood pressure were lower in combined with torasemil group than those in bisoprolol group[(106±10)vs.(111±11),(76±10)vs.(80±10),P<0.05].There was no significant difference in the incidence of adverse reactions and adverse events between the two groups(P>0.05).The electrophysiological indexes decreased in the two groups,more obvious in combined with tolasemide group(P<0.05).Conclusion:Bisoprolol combined with torasemide is safe and effective in the treatment of patients with chronic heart failure.
作者
胡杰锋
曹迎笑
高春香
Hu Jiefeng;Cao Yingxiao;Gao Chunxiang(Department of Rheumatology and Immunology of Senile Diseases,Boluo County People's Hospital,Huizhou City,Guangdong Province,516000,China)
出处
《现代电生理学杂志》
2019年第4期208-213,共6页
Journal of Modern Electrophysiology
关键词
比索洛尔
托拉塞米
心力衰竭
心脏电生理
Bisoprolol
Torasemide
Heart failure
Cardiac electrophysiology
